Objective:To assess the pharmacoeconomic benefits of using omalizumab in the treatment of seasonal allergic rhinitis (SAR) before the pollen season.Methods:This economic evaluation, which based on a prospective, randomized, controlled, open label, single center trial conducted in 2020, compared omalizumab treatment with standard medicine treatment in controlling SAR symptoms two weeks before autumn pollen season. Total nasal symptom scores (TNSS) were used as the effect index for cost-effectiveness analysis (CEA), with incremental cost-effectiveness ratio (ICER) calculated. Cost-utility analysis (CUA) was used to compare incremental cost-utility ratios (ICUR) between groups using 1.76 times of the national and Beijing per capita GDP as willingness-to-pay thresholds. The experimental group was divided into mild and moderate-severe groups for cost-effectiveness analysis.Results:CEA showed an ICER of 3 084.76 yuan/point. CUA revealed an ICUR of 554 288.39 yuan, exceeding 1.76 times of the 2020 national (126 417.28 yuan) and Beijing (288 918.08 yuan) per capita GDP. Therefore, omalizumab currently lacked economic advantage in both Beijing and nationwide. The moderate-severe subgroup had a lower ICUR (371 041.07 yuan/year) than the mild subgroup (1 436, 823.35 yuan/year). Omalizumab would gain economic advantage in Beijing if its cost dropped below 723.02 yuan/dose, and nationwide below 312.72 yuan/dose. For moderate-severe patients, the cost threshold for Beijing was 1 104.95 yuan/dose, and 482.45 yuan/dose nationwide.Conclusions:At its current price, a single pre-pollen season omalizumab injection (300 mg) offers no pharmacoeconomic advantage over conventional medication in improving SAR patients′ quality of life in Beijing and nationwide. However, omalizumab shows lower ICUR in moderate-severe SAR patients compared to mild cases.

Objective:To investigate the epidemiological characteristics of allergic rhinitis (AR) among adults in Yinchuan, focusing on its prevalence and associated risk factors in recent years.Methods:A cross-sectional epidemiological survey was conducted among adult residents in Yinchuan from June to October 2022, including three districts, two counties, and one city, to identify and analyze factors influencing the incidence of AR in the population.Results:A total of 3 345 individuals were surveyed, including 1 891 males (56.5%) and 1 454 females (43.5%). The overall AR prevalence was 17.2% (576/3 345). The self-reported prevalence was 16.2% (306/1 891) in males and 18.6% (270/1 454) in females, with no statistically significant difference ( χ2=3.29, P=0.07). The prevalence was significantly lower among the elderly (aged over 60 years) at 11.8% (60/509) compared to the middle-aged (aged 40-59 years) at 17.1% (202/1 183) and young adults (aged 18-39 years) at 19.0% (314/1 653, χ2=10.36, P=0.023). Han nationality had the highest self-reported prevalence (18.8%, 446/2 372), followed by other ethnic minorities (17.6%, 13/74), and Hui nationality (13.0%, 117/899; χ2=11.21, P=0.004). Regionally, Xingqing District had the highest self-reported prevalence at (19.5%, 188/964), followed by Jinfeng District (18.7%, 151/808), Lingwu City (17.5%, 58/332), Xixia District (14.9%, 78/522), Yongning County (14.3%, 49/342), and Helan County (13.8%, 52/377; χ2=35.68, P=0.038). In terms of disease severity, mild cases made up 55.4% (319/576), while moderate to severe cases constituted 44.6% (257/576). In terms of symptom characteristics, perennial AR patients accounted for 18.8% (108/576), seasonal AR patients accounted for 81.2% (468/576), and 25.7% (148/576) of self-reported AR patients had other allergic diseases. Regarding diagnosis and treatment, 38.7% (223/576) of patients underwent allergen tests, 65.1% (375/576) received medication, but 62.3% (359/576) reported symptoms persisting for 2-year post-treatment, 32.6% (188/576) reported uncontrolled symptoms, and 5% (29/576) experienced symptoms worsening. Conclusions:The study provides a preliminary understanding of the epidemiological characteristics of AR in Yinchuan. These findings provide a reference for formulating relevant public health policies, clarifying prevention and treatment strategies, and improving the prevention and control system for AR.

Objective:To assess the pharmacoeconomic benefits of using omalizumab in the treatment of seasonal allergic rhinitis (SAR) before the pollen season.Methods:This economic evaluation, which based on a prospective, randomized, controlled, open label, single center trial conducted in 2020, compared omalizumab treatment with standard medicine treatment in controlling SAR symptoms two weeks before autumn pollen season. Total nasal symptom scores (TNSS) were used as the effect index for cost-effectiveness analysis (CEA), with incremental cost-effectiveness ratio (ICER) calculated. Cost-utility analysis (CUA) was used to compare incremental cost-utility ratios (ICUR) between groups using 1.76 times of the national and Beijing per capita GDP as willingness-to-pay thresholds. The experimental group was divided into mild and moderate-severe groups for cost-effectiveness analysis.Results:CEA showed an ICER of 3 084.76 yuan/point. CUA revealed an ICUR of 554 288.39 yuan, exceeding 1.76 times of the 2020 national (126 417.28 yuan) and Beijing (288 918.08 yuan) per capita GDP. Therefore, omalizumab currently lacked economic advantage in both Beijing and nationwide. The moderate-severe subgroup had a lower ICUR (371 041.07 yuan/year) than the mild subgroup (1 436, 823.35 yuan/year). Omalizumab would gain economic advantage in Beijing if its cost dropped below 723.02 yuan/dose, and nationwide below 312.72 yuan/dose. For moderate-severe patients, the cost threshold for Beijing was 1 104.95 yuan/dose, and 482.45 yuan/dose nationwide.Conclusions:At its current price, a single pre-pollen season omalizumab injection (300 mg) offers no pharmacoeconomic advantage over conventional medication in improving SAR patients′ quality of life in Beijing and nationwide. However, omalizumab shows lower ICUR in moderate-severe SAR patients compared to mild cases.

Objective:To investigate the epidemiological characteristics of allergic rhinitis (AR) among adults in Yinchuan, focusing on its prevalence and associated risk factors in recent years.Methods:A cross-sectional epidemiological survey was conducted among adult residents in Yinchuan from June to October 2022, including three districts, two counties, and one city, to identify and analyze factors influencing the incidence of AR in the population.Results:A total of 3 345 individuals were surveyed, including 1 891 males (56.5%) and 1 454 females (43.5%). The overall AR prevalence was 17.2% (576/3 345). The self-reported prevalence was 16.2% (306/1 891) in males and 18.6% (270/1 454) in females, with no statistically significant difference ( χ2=3.29, P=0.07). The prevalence was significantly lower among the elderly (aged over 60 years) at 11.8% (60/509) compared to the middle-aged (aged 40-59 years) at 17.1% (202/1 183) and young adults (aged 18-39 years) at 19.0% (314/1 653, χ2=10.36, P=0.023). Han nationality had the highest self-reported prevalence (18.8%, 446/2 372), followed by other ethnic minorities (17.6%, 13/74), and Hui nationality (13.0%, 117/899; χ2=11.21, P=0.004). Regionally, Xingqing District had the highest self-reported prevalence at (19.5%, 188/964), followed by Jinfeng District (18.7%, 151/808), Lingwu City (17.5%, 58/332), Xixia District (14.9%, 78/522), Yongning County (14.3%, 49/342), and Helan County (13.8%, 52/377; χ2=35.68, P=0.038). In terms of disease severity, mild cases made up 55.4% (319/576), while moderate to severe cases constituted 44.6% (257/576). In terms of symptom characteristics, perennial AR patients accounted for 18.8% (108/576), seasonal AR patients accounted for 81.2% (468/576), and 25.7% (148/576) of self-reported AR patients had other allergic diseases. Regarding diagnosis and treatment, 38.7% (223/576) of patients underwent allergen tests, 65.1% (375/576) received medication, but 62.3% (359/576) reported symptoms persisting for 2-year post-treatment, 32.6% (188/576) reported uncontrolled symptoms, and 5% (29/576) experienced symptoms worsening. Conclusions:The study provides a preliminary understanding of the epidemiological characteristics of AR in Yinchuan. These findings provide a reference for formulating relevant public health policies, clarifying prevention and treatment strategies, and improving the prevention and control system for AR.

Objective:To explore the clinical outcome and applicability of the comb flap technique and stepwise design concept in plastic aesthetic and reconstructive surgery.Methods:The clinical data of patients who underwent plastic aesthetic and reconstructive surgery with the comb flap technique in Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2018 to December 2022 were retrospectively analyzed. The application of the comb flap technique follows the concept of stepwise design, that was, preoperative and intraoperative design and adjustment were carried out step by step and in sequence, and the design was combined with the surgical procedure. Its main operations included: an incision was designed along the edge of the target area, the tissue flap was widely separated at the base of the target area. The tissue flap was cut in sequence perpendicular to the cutting edge and temporarily sutured and fixed, the edge was cut and fixed. During the operation, the tension of the incision and the local appearance could be adjusted. The incisal edge was finely sutured, and the temporary suture was finally removed. The healing of surgical incision and complications were observed after the operation, and the facial recovery and surgical effect were followed up.Results:Six patients were enrolled, including 3 males and 3 females, aged from 2 to 58 years. One patient underwent upper eyelid tightening and lower eyelid blepharoplasty through subeyebrow incision. One patient underwent middle and lower face rhytidectomy. One patient underwent thick lip thinning and right facial liposuction. One patient underwent facial congenital melanocytic nevi resection. One patient underwent eyebrow congenital melanocytic nevus resection. One patient underwent facial flap repair. All patients had primary healing of incision, and no surgery-related complications occurred. All patients were followed up for 3 to 18 months, and all patients were satisfied with the surgical effect.Conclusion:The application of comb flap technique and stepwise design concept in plastic aesthetic and reconstructive surgery can delicately adjust the alignment of the incision margin, make the tension evenly distributed, and reduce the risk of scar formation and deformity after the operation. It has a wide range of clinical applications and good applicability.

Objective:To explore the clinical outcome and applicability of the comb flap technique and stepwise design concept in plastic aesthetic and reconstructive surgery.Methods:The clinical data of patients who underwent plastic aesthetic and reconstructive surgery with the comb flap technique in Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from January 2018 to December 2022 were retrospectively analyzed. The application of the comb flap technique follows the concept of stepwise design, that was, preoperative and intraoperative design and adjustment were carried out step by step and in sequence, and the design was combined with the surgical procedure. Its main operations included: an incision was designed along the edge of the target area, the tissue flap was widely separated at the base of the target area. The tissue flap was cut in sequence perpendicular to the cutting edge and temporarily sutured and fixed, the edge was cut and fixed. During the operation, the tension of the incision and the local appearance could be adjusted. The incisal edge was finely sutured, and the temporary suture was finally removed. The healing of surgical incision and complications were observed after the operation, and the facial recovery and surgical effect were followed up.Results:Six patients were enrolled, including 3 males and 3 females, aged from 2 to 58 years. One patient underwent upper eyelid tightening and lower eyelid blepharoplasty through subeyebrow incision. One patient underwent middle and lower face rhytidectomy. One patient underwent thick lip thinning and right facial liposuction. One patient underwent facial congenital melanocytic nevi resection. One patient underwent eyebrow congenital melanocytic nevus resection. One patient underwent facial flap repair. All patients had primary healing of incision, and no surgery-related complications occurred. All patients were followed up for 3 to 18 months, and all patients were satisfied with the surgical effect.Conclusion:The application of comb flap technique and stepwise design concept in plastic aesthetic and reconstructive surgery can delicately adjust the alignment of the incision margin, make the tension evenly distributed, and reduce the risk of scar formation and deformity after the operation. It has a wide range of clinical applications and good applicability.

Objective:To study the short-term clinical outcomes of different courses of antenatal corticosteroids (ACS) for preterm twins.Methods:From January 2017 to December 2021, preterm twins with gestational age (GA) 24-34 weeks admitted to the neonatal ward of our hospital and received ACS were retrospectively studied. The infants were assigned into single-course group, partial-course group and multiple-course group according to ACS courses. The short-term clinical outcomes were compared among the groups. SPSS software version 25.0 was used for statistical analysis.Results:A total of 286 infants were enrolled in this study, including 128 in single-course group, 89 in partial-course group and 69 in multiple-course group. Compared with single-course group, the risks of neonatal respiratory distress syndrome (RDS) in both partial-course group ( OR=2.332, 95% CI 1.028-5.293, P=0.043) and multiple-course group ( OR=3.872, 95% CI 1.104-13.584, P=0.034) were higher. The birth length in multiple-course group ( β=-0.016, 95% CI -0.029 - -0.002, P=0.024) was lower than single-course group. Conclusions:The risks of neonatal RDS in preterm twins are higher in partial-course and multiple-course of ACS. A full course of ACS should be used to prevent neonatal RDS until further evidence of effectiveness is available.

Objective:To investigate the efficacy and safety of a novel dose adjustment schedule based on subcutaneous immunotherapy (SCIT) after a 16 weeks delayed injection during the maintenance period.Methods:Sixty-eight patients with allergic rhinitis (AR) who received dust mite cluster SCIT and had interrupted treatment for more than 16 weeks during the maintenance period were recruited at Beijing TongRen Hospital, from July to September 2020. They were randomly divided into the novel schedule group ( n=34) and the guideline recommended schedule group ( n=34). In addition, 34 patients who received dust mite SCIT at the same period were selected as the continuous treatment group ( n=34). When receiving treatment again after delayed injection, the novel schedule group was injected directly with the initial dose of maintenance period (10 000 SQ), and the guideline recommended schedule group started the dosage accumulation again from the lowest dose (10 SQ), while the continuous treatment group was injected according to the original schedule. Changes in the combined symptom and medication score (CSMS) from baseline after 3 years of SCIT were used as the primary efficacy evaluation index. Local and systemic adverse events were recorded to evaluate safety. SPSS 23.0 was used for statistical analysis. Results:At the end of 3 years, CSMS in all three groups decreased significantly from baseline, and there was no significant difference in the 3-year change value of CSMS from baseline between the novel schedule group and the guideline recommended schedule group (-1.0±0.3 vs -1.3±0.4, P=0.655). There was also no significant difference in the change of CSMS between the two dose-adjusted groups and the continuous treatment groups (-0.8±0.3 vs -1.3±0.3, P=0.156). No systemic adverse events occurred between the novel schedule group and the guideline recommended schedule group after restarting treatment, and there was no significant difference in frequency of adverse events (0.5% vs 0.5%, P=0.698). Conclusion:There is no significant difference in efficacy and safety between the novel dose adjustment schedule and the recommended dose adjustment schedule when SCIT interrupted injection for more than 16 weeks. Furthermore, SCIT discontinuation of injection for more than 16 weeks doesn′t significantly impact on 3-year efficacy.

Objective:To investigate the changes in total radioactivity in patient body with differentiated thyroid carcinoma (DTC) after 131I treatment and the factors influencing its metabolism. Methods:The clinical data from 218 patients after DTC treatment in the Department of Nuclear Medicine, the Second Affiliated Hospital of Air Force Medical University from September 2021 to April 2022 were retrospectively analyzed. Based on administrated 131I dose, 171 patients were divided into low-dose group (≤ 3.7 GBq) and 47 into high-dose group (>3.7 GBq) . A whole body dynamic radiation monitoring system was used to measure the in vivo residual activity of 131I 24, 48 and 72 h after 131I administration and to explore their influencing factors. Results:24, 48 and 72 h after adimination of 131I, the residual activity of 131I in the low-dose group patients was significantly lower than in the high-dose group patients ( t= -7.46, -3.31, -2.01, P<0.05) . The discharge compliance rate at 24 and 48 h in the low-dose group was significantly higher than that in the high-dose group (21.0% vs. 4.3%, 98.2% vs. 89.4%, χ2 = 7.23, 5.91, P<0.05) , and all patients could meet the discharge criteria at 72 h. Univariate analysis showed that the residual 131I activity at 24 and 48 h was dependent on age, body mass index (BMI) , basal metabolism rate (BMR) and thyroid stimulating hormone (TSH) . As have been shown by multiple linear regression analysis, in the low-dose group, the older age, the higher BMR and the higher TSH level at 24 h tended to the higher 131I residual activity in the body. At 48 h, the higher BMI and the higher TSH level lead to the higher 131I residual activity in patient body. Meanwhile, in the high-dose group, the higher age and BMR at 24 h, tended to the higher in vivo131I residual activity. The influencing factors were analyzed in terms that 131I residual activity reaching 400 MBq in patient body at 24 and 36 h. The result showed that at 24 h the lower TSH level leaded to the lower 131I residual activity in patient body. At 36 h, the younger age, the lower TSH level, and the smaller 131I treatment dose tended to the lower in vivo131I residual activity. Conclusions:Age, BMI, BMR and TSH levels are the influencing factors for the change in total activity in patient body after 131I treatment of DTC. Radiation dose assessment based on the above indicators can provide a reference for adjusting the length of hospitalization time.

Objective:To study the functional connectivity (FC) and metabolic effective connectivity (MEC) patterns of the default mode network (DMN) in healthy male adults based on a novel hybrid PET/MR system.Methods:Fifteen healthy male adults with median age of 29 years were recruited locally in Xi′an from January to May 2019. All subjects went through PET/MR scan to get the whole brain 18F-fluorodeoxyglucose (FDG) PET, resting-state functional MRI (fMRI) and magnetization prepared rapid gradient echo (MPRAGE) T 1 weighted imaging data. CONN18b and statistical parametric mapping (SPM) 12 softwares were used to analyze data. The voxel-wise FC and FDG metabolic data were extracted within 4 sub-networks of DMN, which included medial prefrontal cortex (MPFC), posterior cingulate cortex (PCC) and bilateral lateral parietal (LP). The FC and MEC between 4 sub-networks were calculated based on merged resting-state fMRI and metabolic data, and analyzed by one-sample t test separately, with Bonferroni correction. Results:FC pathways were all significant within 4 sub-networks of DMN ( t values: 6.00-7.71, all P<0.008, Bonferroni corrected). Meanwhile, there were significant bi-directional MEC between MPFC and PCC(MPFC to PCC: t=10.03; PCC to MPFC: t=3.73, both P<0.004, Bonferroni corrected), as well as between bilateral LP (LP_L to LP_R: t=5.28; LP_R to LP_L: t=4.76, both P<0.004, Bonferroni corrected). There were significant uni-directional MEC from both MPFC and PCC to bilateral LP ( t values: 3.44-6.93, all P<0.004, Bonferroni corrected). Conclusions:Special FC and MEC patterns exist within DMN. The closely interrelated MPFC and PCC play more important roles in DMN, and they may mediate LP jointly. The novel integrated PET/MR system will bring new perspective on the organization of brain networks, which may deepen the comprehensive understanding of DMN.